These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11958997)

  • 1. Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.
    Krumme D; Tschesche H
    Bioorg Med Chem Lett; 2002 Mar; 12(6):933-6. PubMed ID: 11958997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxamate derivatives of substrate-analogous peptides containing aminomalonic acid are potent inhibitors of matrix metalloproteinases.
    Krumme D; Wenzel H; Tschesche H
    FEBS Lett; 1998 Oct; 436(2):209-12. PubMed ID: 9781680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
    Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
    J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.
    Steinman DH; Curtin ML; Garland RB; Davidsen SK; Heyman HR; Holms JH; Albert DH; Magoc TJ; Nagy IB; Marcotte PA; Li J; Morgan DW; Hutchins C; Summers JB
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2087-92. PubMed ID: 9873491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.
    Levin JI; Gu Y; Nelson FC; Zask A; DiJoseph JF; Sharr MA; Sung A; Jin G; Cowling R; Chanda P; Cosmi S; Hsiao CL; Edris W; Wilhelm J; Killar LM; Skotnicki JS
    Bioorg Med Chem Lett; 2001 Jan; 11(2):239-42. PubMed ID: 11206468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
    Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
    J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMPs inhibitors: new succinylhydroxamates with selective inhibition of MMP-2 over MMP-3.
    Marcq V; Mirand C; Decarme M; Emonard H; Hornebeck W
    Bioorg Med Chem Lett; 2003 Sep; 13(17):2843-6. PubMed ID: 14611841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
    Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
    J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.
    Scozzafava A; Supuran CT
    J Med Chem; 2000 Oct; 43(20):3677-87. PubMed ID: 11020282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
    J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
    Yao W; Wasserman ZR; Chao M; Reddy G; Shi E; Liu RQ; Covington MB; Arner EC; Pratta MA; Tortorella M; Magolda RL; Newton R; Qian M; Ribadeneira MD; Christ D; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3347-50. PubMed ID: 11585439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.
    Campbell DA; Xiao XY; Harris D; Ida S; Mortezaei R; Ngu K; Shi L; Tien D; Wang Y; Navre M; Patel DV; Sharr MA; DiJoseph JF; Killar LM; Leone CL; Levin JI; Skotnicki JS
    Bioorg Med Chem Lett; 1998 May; 8(10):1157-62. PubMed ID: 9871727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
    Hanessian S; Moitessier N; Gauchet C; Viau M
    J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.
    Sjøli S; Nuti E; Camodeca C; Bilto I; Rossello A; Winberg JO; Sylte I; Adekoya OA
    Eur J Med Chem; 2016 Jan; 108():141-153. PubMed ID: 26638045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids.
    Odake S; Morita Y; Morikawa T; Yoshida N; Hori H; Nagai Y
    Biochem Biophys Res Commun; 1994 Mar; 199(3):1442-6. PubMed ID: 8147888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.